The MAESTRIA project: using artificial intelligence to drive innovation
MAESTRIA, an ultra-innovative project to better detect the atrial cardiomyopathy responsible for the onset of atrial fibrillation and embolic vascular accidents
Atrial fibrillation (AF) is the most common heart rhythm disorder. Its incidence and prevalence are increasing rapidly, mainly in relation to the aging of the population. It is estimated that 750,000 people in France suffer from atrial fibrillation. The high cost of treatment is estimated at around 2.5 billion euros per year.
The MAESTRIA project (Machine Learning and Artificial Intelligence for Early Detection of Stroke and Atrial Fibrillation) is a consortium of 18 partners from Europe, the United States and Canada responding to a H2020 call for projects on digital diagnosis.
What is a H2020 call for projects?
Horizon 2020 (2014-2020) is the European Union’s research and innovation funding program. This program aims to support resolutely interdisciplinary research projects, likely to respond to major economic and social challenges. It was succeeded by Horizon Europe (2021-2027).
What's at stake for the MAESTRIA project?
Atrial fibrillation, a heart rhythm disorder, is the most common cardiac arrhythmia and the leading cause of strokes in the heart. Frequently associated with heart failure, high blood pressure, but also with obesity and diabetes, AF affects approximately 1% of the general population and up to 8% of people over 80 years of age.
The challenge today in the clinical management of atrial fibrillation is to intervene before the onset of the arrhythmia, ie from the first signs of atrial cardiomyopathy.
Coordinated by Prof. Stéphane Hatem, director of the IHU-ICAN and of research unit 1166 at Sorbonne University, the MAESTRIA project therefore aims to develop a new approach for the rapid detection of atrial cardiomyopathy.
All the expertise of IHU ICAN at the service of MAESTRIA
Lasting 5 years, this project requires several expertise within the IHU-ICAN:
- Our Scientific Operations Department (SOS) for setting up and monitoring the project
- Our legal department (PJV) for regulatory and ethical aspects
- La plateforme d’imagerie ICAN Imaging pour l’interprétation des données d’imagerie et d’ECG et l’identification des algorithmes les plus appropriés à intégrer dans le démonstrateur MAESTRIA.
- The clinical platform and the Omics platform of the IHU-ICAN to define the electrophysiological signature of the disease
- The Biological Resource Center (CRB) for the proper conservation of the biological data of the study
The importance of data
By combining imaging data with patient physiological data (omics, clinical data, etc.), this platform will be able to identify new therapeutic targets for improved diagnostic accuracy and increase the effectiveness and efficiency of treatments by enabling better prevention of complications of atrial cardiomyopathy, such as atrial fibrillation and stroke.
